International Journal of Drug Delivery Technology
Volume 16, Issue 15s, 2026
Study Protocol

Study Protocol Of Randomised Controlled Clinical Trial On Add On Effect Of Mashabaladi Kashaya Along With Panchakarma Therapy In The Management Of Spastic Cerebral Palsy In Children

Dr. Sayali Gangurde1*, Dr. Rajagopala S2, Dr. Arun Kumar Mahapatra3

1*PhD Scholar, Department of Kaumarbhritya, All India Institute of Ayurveda, Gautampuri, Sarita Vihar, Mathura Road, New Delhi

2Professor & HoD, Dept. of Kaumarabhritya, Dean Research & Associate Dean International Cell, All India Institute of Ayurveda, Gautampuri, Sarita Vihar, Mathura Road, New Delhi

3Associate Professor, Dept. of Kaumarabhritya, All India Institute of Ayurveda, Gautampuri, Sarita Vihar, Mathura Road, New Delhi


ABSTRACT

Background: Spastic cerebral palsy (SCP) is the most common form of cerebral palsy, characterized by increased muscle tone and impaired motor function. Integrative therapies such as Panchakarma may improve outcomes, and Mashabaladi Kashaya may enhance therapeutic effects.

Objective: To evaluate the add-on effect of Mashabaladi Kashaya along with Panchakarma therapy in children with spastic cerebral palsy.

Methods: A randomized controlled clinical trial with two parallel groups was conducted over 48 days, followed by a 3-month follow-up. Children aged 1–10 years with SCP were randomly assigned to the trial group (Panchakarma with Mashabaladi Kashaya) or control group (Panchakarma only). Outcome measures included Modified Ashworth Scale, Goniometry, GMFM, MRC Scale, and Barthels Index.

Trial Status: Recruitment and intervention have been completed.

Outcome: The study is expected to demonstrate improvements in spasticity, mobility, and functional outcomes with combined therapy.

Keywords: NA

How to cite this article: Gangurde S, Rajagopala S, Mahapatra AK. Study Protocol Of Randomised Controlled Clinical Trial On Add On Effect Of Mashabaladi Kashaya Along With Panchakarma Therapy In The Management Of Spastic Cerebral Palsy In Children. Int J Drug Deliv Technol. 2026;16(15s): 1097-1102. DOI: 10.25258/ijddt.16.15s.121

Source of support: Nil.

Conflict of interest: None